NCT02978404View on ClinicalTrials.gov

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

January 31, 2021

Study Completion Date

December 31, 2023

Conditions
Clear-Cell Metastatic Renal Cell CarcinomaNon Small Cell Lung Cancer MetastaticBrain Metastases, AdultSmall Cell Lung CancerMelanoma
Interventions
DRUG

Nivolumab

Nivolumab is administered to patients to a maximum of 2 year.

RADIATION

Radiosurgery

Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.

Trial Locations (4)

H2L 4M1

Centre Hospitalier de l'Université de Montréal, Montreal

H3T 1E2

Jewish General Hospital, Montreal

H4A 3J1

McGill University Health Centre, Montreal

J1H 5N4

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER